Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone

Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone

Objectives: This retrospective cohort study aims to explore head-to-head clinical outcomes and complications associated with tocilizumab or baricitinib initiation among hospitalized COVID-19 patients receiving dexamethasone.Methods: Among 10,445 COVID-19 patients hospitalized between January 21st 20...

Full description

Bibliographic Details
Main Authors: Carlos K. H. Wong, Kristy T. K. Lau, Ivan C. H. Au, Xi Xiong, Matthew S. H. Chung, Belle Y. C. Leung, Eric H. Y. Lau, Benjamin J. Cowling
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Pharmacology
Subjects:
baricitinib
clinical improvement
COVID-19
dexamethasone
tocilizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.866441/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.866441/full

Similar Items